泰林生物
(300813)
| 流通市值：15.56亿 | | | 总市值：22.16亿 |
| 流通股本：8512.61万 | | | 总股本：1.21亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 163,194,894.73 | 155,451,865.25 | 148,853,721.98 | 149,088,376.64 |
| 交易性金融资产 | 45,151,580 | 37,100,000 | 80,100,000 | 61,120,441.21 |
| 应收票据及应收账款 | 46,915,123.01 | 55,441,771.81 | 47,105,838.29 | 55,073,932.77 |
| 应收账款 | 46,915,123.01 | 55,441,771.81 | 47,105,838.29 | 55,073,932.77 |
| 应收款项融资 | 15,662,821.01 | 8,764,689.34 | 17,202,098.35 | 12,778,553.43 |
| 预付款项 | 5,978,530.99 | 6,081,493.14 | 3,545,706.44 | 4,101,853.88 |
| 其他应收款合计 | 7,076,978.42 | 7,654,832.04 | 6,028,789.06 | 7,403,136.38 |
| 存货 | 144,382,566.85 | 136,452,748.1 | 133,422,928.06 | 126,535,071.63 |
| 合同资产 | 7,631,896.85 | 6,904,907.97 | 5,929,333 | 4,967,260.85 |
| 其他流动资产 | 109,971,216.38 | 109,666,354.22 | 109,860,732.37 | 128,781,141.12 |
| 流动资产合计 | 545,965,608.24 | 523,518,661.87 | 552,049,147.55 | 549,849,767.91 |
| 非流动资产: | | | | |
| 其他债权投资 | 55,518,917.82 | 55,819,673.98 | 45,543,997.26 | 55,452,627.4 |
| 长期股权投资 | 11,251,435.86 | 11,104,836.63 | 10,546,523.82 | 10,549,721.85 |
| 投资性房地产 | 8,323,585.76 | 8,399,509 | 8,475,432.25 | 8,551,355.56 |
| 固定资产 | 241,371,333.51 | 244,342,116.18 | 247,514,853.54 | 250,792,052.78 |
| 在建工程 | 45,739,661.38 | 39,161,752.01 | 16,363,513.83 | 9,259,817.63 |
| 无形资产 | 26,690,098.3 | 26,994,622.93 | 27,193,563.16 | 27,392,503.39 |
| 长期待摊费用 | 27,068,321.2 | 28,112,311.4 | 28,933,750.62 | 29,069,749.33 |
| 递延所得税资产 | 162,967.39 | 158,565 | 169,460.81 | 169,460.81 |
| 其他非流动资产 | 152,600 | 152,600 | 10,117,100 | 17,885,526.73 |
| 非流动资产合计 | 416,278,921.22 | 414,245,987.13 | 394,858,195.29 | 409,122,815.48 |
| 资产总计 | 962,244,529.46 | 937,764,649 | 946,907,342.84 | 958,972,583.39 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 20,054,824.64 | 30,769,872.42 | 15,815,835.34 | 15,858,863.2 |
| 应付账款 | 20,054,824.64 | 30,769,872.42 | 15,815,835.34 | 15,858,863.2 |
| 合同负债 | 92,605,083.31 | 72,340,074.77 | 68,573,213.04 | 65,727,476.61 |
| 应付职工薪酬 | 21,004,075.63 | 16,424,180.01 | 14,172,051.5 | 28,000,225.11 |
| 应交税费 | 3,759,395.96 | 3,210,820.51 | 4,699,163.32 | 5,069,396.07 |
| 其他应付款合计 | 7,569,641.26 | 13,710,705.2 | 27,715,300.95 | 30,935,912.34 |
| 其他流动负债 | 8,790,812.84 | 8,399,483.37 | 6,937,920.95 | 6,543,946.12 |
| 流动负债合计 | 153,783,833.64 | 144,855,136.28 | 137,913,485.1 | 152,135,819.45 |
| 非流动负债: | | | | |
| 递延所得税负债 | 2,248,346.51 | 2,184,366.92 | 2,545,336.65 | 2,545,336.65 |
| 非流动负债合计 | 2,248,346.51 | 2,184,366.92 | 2,545,336.65 | 2,545,336.65 |
| 负债合计 | 156,032,180.15 | 147,039,503.2 | 140,458,821.75 | 154,681,156.1 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 121,199,219 | 121,199,219 | 121,199,219 | 121,199,219 |
| 资本公积 | 401,944,666.77 | 414,449,343.7 | 413,456,193.44 | 412,503,433.9 |
| 减:库存股 | - | 32,285,577.51 | - | - |
| 盈余公积 | 27,628,568.73 | 31,190,070.38 | 27,628,568.73 | 27,628,568.73 |
| 未分配利润 | 255,439,894.81 | 256,172,090.23 | 244,164,539.92 | 242,960,205.66 |
| 归属于母公司股东权益合计 | 806,212,349.31 | 790,725,145.8 | 806,448,521.09 | 804,291,427.29 |
| 股东权益合计 | 806,212,349.31 | 790,725,145.8 | 806,448,521.09 | 804,291,427.29 |
| 负债和股东权益合计 | 962,244,529.46 | 937,764,649 | 946,907,342.84 | 958,972,583.39 |
| 公告日期 | 2026-10-30 | 2026-08-27 | 2026-04-30 | 2026-03-27 |
| 审计意见(境内) | | | | 标准无保留意见 |